Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-30

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tests the hypothesis that endogenous bradykinin contributes to effects of a combined angiotensin receptor blocker/neprilysin inhibitor (LCZ696 or Entresto)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109

Heart Failure

COMPLETED PHASE4

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

NCT03553810

Hypertensive Heart Disease

COMPLETED PHASE2

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

NCT02554890

Acute Heart Failure

COMPLETED PHASE4

Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria

NCT00369538

Proteinuria Hypertension End Stage Renal Disease

SUSPENDED PHASE4

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114

Hemodialysis Hypertension Left Ventricular Hypertrophy

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with heart failure (HF) with reduced ejection fraction who qualify for the study will undergo a three-week run-in period in which any prior angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker they were taking will be discontinued and they will be given valsartan 80 mg bid in a single-blind fashion. After the run-in, subjects will undergo four study periods in random order. During two study periods they will receive enalapril 10 mg bid and during two they will receive sacubitril/valsartan (LCZ696) 200 mg bid for seven days. On the seventh day or each period, subjects will complete a study day in which they are randomized to receive either the bradykinin B2 receptor blocker icatibant or placebo intravenously. Each study period will be separated by a three-week washout during which subjects receive valsartan 80 mg bid.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure NYHA Class I Heart Failure NYHA Class II Heart Failure NYHA Class III

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

S/V+Pla, S/V+I, Enal+Pla, Enal+I

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

S/V+Pla, Enal+I, S/V+I, Enal+Pla

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

S/V+Pla, Enal+Pla, Enal+I, S/V+I

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

S/V+I, S/V+Pla, Enal+I, Enal+P

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

S/V+I, Enal+Pla, S/V+Pla, Enal+I

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

S/V+I, Enal+I, Enal+Pla, S/V+Pla

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Enal+Pla, S/V+Pla, S/V+I, Enal+I

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Enal+Pla, S/V+I, Enal+I, S/V+Pla

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Enal+Pla, Enal+I, S/V+Pla, S/V+I

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Enal+I, S/V+Pla, Enal+Pla, S/V+I

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Enal+I, S/V+I, S/V+Pla, Enal+Pla

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Enal+I, Enal+Pla, S/V+I, S/V+Pla

Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.

Group Type EXPERIMENTAL

Valsartan 80 mg bid

Intervention Type DRUG

oral medication during run-in and washout period

Enalapril 10 mg bid

Intervention Type DRUG

oral medication

Sacubitril-Valsartan 200 mg bid

Intervention Type DRUG

oral medication

Icatibant

Intervention Type DRUG

intravenous medication

Placebo

Intervention Type DRUG

intravenous medication

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Valsartan 80 mg bid

oral medication during run-in and washout period

Intervention Type DRUG

Enalapril 10 mg bid

oral medication

Intervention Type DRUG

Sacubitril-Valsartan 200 mg bid

oral medication

Intervention Type DRUG

Icatibant

intravenous medication

Intervention Type DRUG

Placebo

intravenous medication

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Stable patients with a reduced EF

1. EF less than or equal to 40% (confirmed by echocardiogram within the last six months), and
2. history of symptoms of New York Heart Association class I, II or III HF
3. stable clinical symptoms including no hospitalizations for the last six months
4. treatment with a stable dose of an ACEi or ARB and with a beta blocker (unless contraindicated or not tolerated) for at least four weeks
5. treatment with a stable dose of an MR antagonist for at least four weeks unless not possible due to renal function or serum potassium.
2. For female subjects, the following conditions must be met:

1. postmenopausal status for at least one year, or
2. status post-surgical sterilization

Exclusion Criteria

1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACEi, ARBs, or NEPi, as well as known or suspected contraindications to the study drugs
2. History of angioedema
3. History of pancreatitis or known pancreatic lesions
4. History of decompensated HF within the last six months (exacerbation of chronic HF manifested by signs and symptoms that required intravenous therapy or hospitalization)
5. History of heart transplant or on a transplant list or with left ventricular assistance device
6. Symptomatic hypotension and/or a SBP\<100 mmHg at screening or \<90 mmHg during the study
7. Serum potassium \>5.2 mmol/L at screening or \>5.4 mmol/L during the study
8. Acute coronary syndrome, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within six months prior to screening
9. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening
10. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack within six months
11. History of ventricular arrhythmia with syncopal episodes
12. Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker
13. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation
14. Presence of other hemodynamically significant obstructive lesions of the left ventricular outflow tract, including aortic and subaortic stenosis
15. Type 1 diabetes
16. Poorly controlled type 2 diabetes mellitus (T2DM), defined as a HgbA1c \>9%
17. Hematocrit \<35%
18. Impaired renal function (eGFR of \<30mL/min/1.73 m2) as determined by the four-variable Modification of Diet in Renal Disease (MDRD) equation, where serum creatinine (Scr) is expressed in mg/dL and age in years:

eGFR (mL/min/1.73m2)=175 • Scr-1.154 • age-0.203 • (1.212 if Black) • (0.742 if female)
19. Use of hormone-replacement therapy
20. Breast feeding and pregnancy
21. History or presence of immunological or hematological disorders
22. History of malignancy other than non-melanoma skin cancer
23. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week
24. Clinically significant gastrointestinal impairment that could interfere with drug absorption
25. Impaired hepatic function \[aspartate amino transaminase (AST) and/or alanine amino transaminase (ALT) \>3.0 x upper limit of normal range\]
26. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with non-steroidal anti-inflammatory drugs
27. Treatment with chronic systemic glucocorticoid therapy within the last year
28. Treatment with lithium salts
29. History of alcohol or drug abuse
30. Treatment with any investigational drug in the one month preceding the study
31. Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
32. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No